Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 9Thoracic 2Dermatologic 2CNS 2Sarcoma 1Other 1Lymphoid 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 5Melanoma 3Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liposarcoma 1Glioma 1Gastrointestinal Stromal Tumors 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1Brain Diseases 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Midazolam × Thoracic × Clear all
NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Pfizer

Phase 1 Terminated
65 enrolled 52 charts
CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT03420742 2023-01-27

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Takeda

Phase 1 Completed
24 enrolled 17 charts
Thoracic

Carcinoma, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡